Inflammatory bowel disease of the lung: The role of infliximab?

Hayek, Adam; Pfanner, Timothy P.; White, Heath

doi:10.1016/j.rmcr.2015.05.012

Cited by 12 publications

(5 citation statements)

References 16 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We decided to start budesonide instead of systemic steroids, to avoid side effects of the latter in this elderly patient, and to allow reimbursement with biological therapies thereafter. Eight cases of symptomatic pulmonary EIM with CD treated with infliximab were reviewed by Hayek et al (10). All of them responded well to infliximab, resulting in clinical and radiologic resolution of the pulmonary EIM.…”

Section: Discussionmentioning

confidence: 99%

A curious presentation of Crohn’s disease with pulmonary involvement: a case report

Haenen

Verstockt

Ferrante

et al. 2023

AGEB

View full text Add to dashboard Cite

Crohn’s disease (CD) is a chronic inflammatory bowel disease often presenting with extraintestinal manifestations. However, pulmonary involvement in CD is quite rare. We here report a case of CD with pulmonary manifestation as the first presenting sign. Thus, immune-mediated inflammatory disorders such as CD should always be kept in the differential list in case of unusual clinical symptoms or radiological signs of idiopathic pulmonary presentations. Crohn’s disease (CD) is a chronic inflammatory bowel disease often presenting with extraintestinal manifestations. However, pulmonary involvement in CD is quite rare. We here report a case of CD with pulmonary manifestation as the first presenting sign. Thus, immune-mediated inflammatory disorders such as CD should always be kept in the differential list in case of unusual clinical symptoms or radiological signs of idiopathic pulmonary presentations.

show abstract

Section: Discussionmentioning

confidence: 99%

A curious presentation of Crohn’s disease with pulmonary involvement: a case report

Haenen

Verstockt

Ferrante

et al. 2023

AGEB

View full text Add to dashboard Cite

show abstract

“…However, compared to normal subjects, those with IBD consistently had decreased D LCO , and it may be significantly lower during active disease [4, 6]. Additionally, corticosteroids are considered the mainstay of therapy in treating pulmonary EIM in Crohn's disease [11]. However, up to one-third of patients fail to respond to treatment or cannot taper off, as seen in this patient.…”

Section: Discussionmentioning

confidence: 99%

A Rare Cause of Pulmonary Nodules

Chew

Chak

Matsukuma

2016

Case Rep Gastroenterol

View full text Add to dashboard Cite

Crohn’s disease is a chronic, idiopathic autoimmune disorder that primarily targets the gastrointestinal (GI) system. It is characterized by transmural inflammation of the GI tract that can occur anywhere from the mouth to the anus. Not infrequently, the disease may also have extraintestinal manifestations (EIMs) that can affect almost any organ system. It is estimated that EIMs affect up to 36% of patients with Crohn’s disease, but the incidence and prevalence of pulmonary involvement are variable in the literature and may be as low as 0.4%. There are few case reports documenting pulmonary manifestations, as they are often overlooked, especially if respiratory symptoms are present before the diagnosis of GI manifestations, as in the present case. A 44-year-old otherwise healthy woman presented with nonspecific respiratory complaints, recurrent pneumonias, and multiple computed tomography images showing diffuse, migratory, nodular, and consolidative parenchymal lung disease, with a largely unremarkable infectious and rheumatologic evaluation. Lung biopsy revealed necrotizing and nonnecrotizing granulomas, raising concern for sarcoidosis. Subsequent imaging revealed an incidental mass in the cecum. Biopsy of the cecum lesion revealed acute cryptitis, crypt abscess, and a single poorly formed granuloma, suggesting the possibility of Crohn’s disease. In this report, we present a patient whose pulmonary manifestations ultimately led to the diagnosis of Crohn’s disease.

show abstract

“…Although not clearly defined in the literature, it is probable that the mechanism of action for infliximab in pulmonary IBD is similar. Infliximab is described in the literature as a management strategy for pulmonary CD [16, 17, 37, 38] including the promising outcome of disease remission.…”

Section: Discussionmentioning

confidence: 99%

Tracheobronchitis in ulcerative colitis: a case report of therapeutic response with infliximab and review of the literature

et al. 2019

View full text Add to dashboard Cite

BackgroundThe extra-intestinal manifestation of tracheobronchitis is a rare complication of ulcerative colitis (UC). Here, we present a case of UC-related tracheobronchitis wherein the positive clinical effects of infliximab are demonstrated.Case presentationWe report the case of a 39-year old woman who presented with a chronic productive cough on a distant background of surgically managed ulcerative colitis (UC). Our patient failed to achieve a satisfactory clinical improvement despite treatment with high dose inhaled corticosteroids, oral corticosteroids and azathioprine. Infliximab therapy was commenced and was demonstrated to achieve macroscopic and symptomatic remission of disease.ConclusionsWe present the first case report documenting the benefits of infliximab in UC-related tracheobronchitis.

show abstract

Inflammatory bowel disease of the lung: The role of infliximab?

Cited by 12 publications

References 16 publications

A curious presentation of Crohn’s disease with pulmonary involvement: a case report

A curious presentation of Crohn’s disease with pulmonary involvement: a case report

A Rare Cause of Pulmonary Nodules

Tracheobronchitis in ulcerative colitis: a case report of therapeutic response with infliximab and review of the literature

Contact Info

Product

Resources

About